The Anglo-Swedish pharmaceutical AstraZeneca reported this Friday that una dose of its Vaxzevria vaccine – the new name for the drug – is “highly effective” in preventing serious cases of covid and hospitalizations caused by the beta and delta variants of the coronavirus.

The study, carried out in Canada with 69,533 infected with SARS-CoV-2 between December 2020 and May 2021, indicated that the preparation reaches a 87 percent efficacy against “hospitalization or death” caused by the delta variant (B.617.2, also known as “Indian”), and a 90 percent to alpha (B.1.1.7 or “Kent”, referring to the English county where it was first detected).

It also has a 82 percent efficacy, after a puncture, against “hospitalization or death” caused by the beta / gamma variant, first identified in South Africa (B.1.351).

Of the total number of individuals analyzed for this study by the Canadian Immunization Research Network (CIRN), 40,828 (9.7%) were positive for any of the variants considered “worrisome”, while 28,705 (6.8%) they were infected with other variants of the coronavirus.

The analysis warns that there was not enough time yet to report on the effectiveness of Vaxzevria after the second dose, although “other studies showed an ‘increased efficacy” after the second puncture.

“The efficacy of Vaxzevria after one dose against hospitalization or death was similar to that of other vaccines tested in the study,” AstraZeneca said in a statement.

The executive vice president of R&D of the Anglo-Swedish company, Mene Pangalos, stressed that this preparation, analyzed with “real world data”, offers “a high level of protection” against the “most serious forms” of covid-19, even after “a single dose”.

“It is essential that we continue to protect as many people as possible in all corners of the world to be able to anticipate this deadly virus,” he added.


Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more